Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Evaluation of Cytotoxic and Apoptotic Effects of Dt386-Br2: A Promising Anticancer Fusion Protein Publisher



Shafiee F1 ; Rabbani M1 ; Jahaniannajafabadi A1
Authors

Source: Journal of Reports in Pharmaceutical Sciences Published:2020


Abstract

Purpose: In the previous studies, we designed an anticancer immunotoxin containing the catalytic and translocation domains of diphtheria toxin fused to BR2, a buforin II-derived antimicrobial peptide as a cancer-specific cell penetrating peptide, in order to target various cancer cells. The aim of this study was to evaluate the in vitro cytotoxicity of DT386-BR2 against K-562 cells as the most famous cell line for leukemia. Materials and Methods: MTT and flow-cytometry assays were used for determining the cytotoxic effects and cell death mechanism of DT386-BR2, respectively, against K-562 cell line. The recombinant DT386 and synthetic BR2 were used as the negative control in cytotoxicity assay. Results: The results of this study showed a significant reduction in survival of K-562 cells caused by DT386-BR2 as compared with BR2 and DT386 fragments. On the contrary, the flow-cytometry results showed apoptosis induction by DT386-BR2 after 12h in a dose- and time-dependent manner. Conclusion: DT386-BR2 fusion protein can be used for further preclinical studies for determining its pharmacokinetic/pharmacodynamic profiles and evaluating its anticancer efficacy in suitable animal models. © 2020 Wolters Kluwer Medknow Publications. All rights reserved.
Other Related Docs
6. Recombinant Production and Intein-Mediated Purification of an Antimicrobial Peptide, Br2, International Journal of Peptide Research and Therapeutics (2017)
8. Application of Antimicrobial Peptides in the Design and Production of Anticancer Agents, International Journal of Peptide Research and Therapeutics (2023)
19. Novel Palladium Complex: Cytotoxicity Against Cisplatin-Resistant K562 Cells, Iranian Journal of Pharmaceutical Research (2019)